Hashtag
Men's Weekly

LTS wins funding from BARDA’s Patch Forward Prize Competition for two partnerships

ANDERNACH, GERMANY - Newsaktuell - 14 January 2025 - LTS LOHMANN Therapie-Systeme AG ("LTS"), a leading pharmaceutical technology company, is proud to announces its selection as a Concept Stage winner for two projects in the #PatchForwardPrize, a $50 million challenge by the Biomedical Advanced Research and Development Authority (BARDA) to advance microneedle patch-based RNA vaccine technologies.



LTS
LTS' proprietary dissolvable microneedle array patch technology with mRNA vaccines aims for the development of next generation vaccine technologies. Source: LTS LOHMANN Therapie-Systeme AG

The Patch Forward Prize, part of the Project NextGen initiative led by BARDA, aims to accelerate next-generation vaccine technologies. By fostering partnerships between vaccine developers and delivery platform innovators, the competition drives progress from concept to clinical stages, paving the way for transformative advancements in global health. Each of the prizes announced today represents an award of US$ 2 million, that will be shared between LTS and its partners.

The awarded projects bring together LTS's proprietary dissolvable Microneedle Array Patch (MAP) technology with mRNA vaccines from two partners, BioNet, a biotech manufacturer specializing in genetically engineered vaccines and PopVax, an Indian full-stack biotechnology company developing broadly-protective mRNA vaccines using machine learning-enabled computational protein design.

Both projects aim to address critical challenges in vaccine stability, delivery, and adaptability, with the potential to improve patient access and compliance. The focus will be on seasonal influenza vaccines, with the ability to pivot to pandemic strains if necessary.

BioNet's approach tackles the ongoing challenge of influenza strain variability by developing a trivalent seasonal influenza mRNA vaccine (mIV3) that targets conserved regions of the hemagglutinin (HA) and neuraminidase (NA) proteins from dominant H1N1, H3N2, and B influenza viruses. These mRNA constructs are carefully selected to elicit broad protective immune responses against seasonal influenza.

PopVax is leading the effort to develop a seasonal influenza vaccine built on their novel mRNA-encoded immunogen display architecture and LNP platform. PopVax's immunogen design and display approach boosts the elicited strain-specific antibody response by as much as 250x in mice in comparison with a leading approved influenza vaccine, leading to significantly lower dosage requirements. This approach also elicits a broader immune response, including robust antibody titer against pandemic H5N1 influenza, a rising threat in the United States, despite not encoding an H5N1-specific immunogen.

LTS CEO Bas van Buijtenen commented: "As a front-runner in drug delivery, we care passionately about solutions that provide better outcomes and better patient experience. We are grateful and proud that Barda's Patch Forward prize provides an opportunity to BioNet, PopVax and LTS to create a breakthrough in vaccine administration. We look forward to delivering on the promise of the combination of our technologies through our joint programs."

"LTS Microneedle-Array-Patch (Map)-Program is proud to have received those 2 awards together with our partners PopVax and BioNet, with their innovative mRNA technologies", added Dr. Frank Theobald, Head of MAP Program at LTS. "The BARDA Patch Forward Price allows combination of 2 breakthrough technologies to be better prepared for the next pandemics to come. The financial support from BARDA will help to advance the MAP technology towards commercialization addressing an unmet medical need and offering the opportunity for self-administration as well as the opportunity for lowering the cold-chain requirements for mRNA."

- Picture is available at AP -


Hashtag: #FEV

The issuer is solely responsible for the content of this announcement.

About LTS

We CARE. We CREATE. We DELIVER. The driving philosophy behind LTS. As a trusted technology partner for the pharmaceutical industry, we develop and manufacture innovative drug delivery systems such as Transdermal Patches ("TTS") and Oral Thin Films ("OTF") as well as wearable drug delivery devices ("OBDS"). LTS´ commercial offering encompasses more than 20 marketed products and a diverse pipeline of more than 40 development projects targeting multiple disease indications. LTS's innovation pipeline contains both partner-funded as well as proprietary, LTS-funded projects. LTS maintains its leading position through the continuous refinement of its core TTS and OTF technologies and by advancing emerging drug delivery technologies, including Microneedle Array Patches ("MAP") for the transdermal delivery of small and large molecules, biological actives and vaccines. With its SorrelTM wearable drug delivery platform LTS offers patient friendly solutions for complex drugs delivery at home. Founded in 1984, LTS operates today from four sites: in Andernach, Germany, West Caldwell, NJ, USA, St. Paul, MN, USA and Netanya, Israel. LTS has also a representative office in Shanghai, China.

Business News

ANDPAD Launches Vietnamese Language Support for its Cloud-Based Construction Project Management Service

Expanding Multilingual Support for Global Users TOKYO, JAPAN - Media OutReach Newswire - 26 June 2025 - ANDPAD Inc. (Head Office: Chiyoda-ku, Tokyo; CEO: Takeo Inada; hereinafter ANDPAD), which opera...

Hashtag.net.au - avatar Hashtag.net.au

Changhong Unveils Smart Living Innovations at 2025 Jakarta Expo, Bringing AI-Driven Appliances to Indonesian Homes

Exclusive Shopee partnership brings cutting-edge smart living technology to Indonesian consumers JAKARTA, INDONESIA - Media OutReach Newswire - 24 June 2025 - Changhong, a global leader in smart hom...

Hashtag.net.au - avatar Hashtag.net.au

Malaysia Launches Full-Scale Startup ASEAN Platform To Drive Regional Growth

PUTRAJAYA, MALAYSIA - Media OutReach Newswire - 26 June 2025 - Malaysia today launched the Startup ASEAN platform, marking the full-scale rollout of a bold, unified digital gateway to connect and empo...

Hashtag.net.au - avatar Hashtag.net.au

Hong Kong Civil Claim Centre Launches Free Work Injury Compensation Calculator

HONG KONG SAR - Media OutReach Newswire - 26 June 2025 - The Hong Kong Civil Claim Centre (hkcivilclaim.com) has officially launched a brand-new online feature: the Work Injury Compensation Calculat...

Hashtag.net.au - avatar Hashtag.net.au

Deleted

This Press release has been killed

Hashtag.net.au - avatar Hashtag.net.au

SiegFund Transforms into SiegPath: A Strategic Rebrand Paving the Way for the Future of Professional Trading

HONG KONG SAR - Media OutReach Newswire - 24 June 2025 - SiegFund, a fintech–driven proprietary trading platform, has officially completed its brand upgrade and will now operate as SiegPath, serving...

Hashtag.net.au - avatar Hashtag.net.au

Health & Wellness

Telehealth Could be the Catalyst for Better Heart Health in Australia

Hashtag.net.au - avatar Hashtag.net.au

Image by stockking on Freepik Heart disease is one of the leading causes of death in Australia despite decades of advancements in medicine and health education campaigns. More than 400 Australians ...

Disability Care in Melbourne: What Families Need to Know in 2025

Hashtag.net.au - avatar Hashtag.net.au

If you’re supporting a loved one with a disability in Melbourne, you’ll know how important it is to find the right care—and how overwhelming it can be to navigate the system. With the National Disab...

Online Medical Certificate Services: Essential Features to Look Out For

Hashtag.net.au - avatar Hashtag.net.au

"Discover top online medical certificate services! Essential features to look for to get trusted and efficient results." Choosing high-quality services is essential for ensuring reliable, efficient, ...